BRIACELL THERAP (BCTX) vs Metagenomi Therapeutics, Inc. (MGX)
- BRIACELL THERAP BCTX 3.42 −9.28%
- Metagenomi Therapeutics, Inc. MGX 0.78 −8.24%
BRIACELL THERAP and Metagenomi Therapeutics, Inc. are both Biotechnology companies. BRIACELL THERAP and Metagenomi Therapeutics, Inc. are of similar size ($32.8M and $31.9M). Metagenomi Therapeutics, Inc. has negative trailing earnings, so its P/E is not meaningful; BRIACELL THERAP trades at 1.5×. BRIACELL THERAP has the higher net margin (0.00% vs −689.2%) and the lower return on invested capital (−3,311.0% vs 0.00%). Across the 13 metrics below, BRIACELL THERAP leads on 7 and Metagenomi Therapeutics, Inc. on 6.
Valuation
Profitability
| Metric | BCTX | MGX | Biotechnology median |
|---|---|---|---|
| Gross margin | 0.00% | 100.00% | 65.16% |
| Operating margin | 0.00% | (741.58%) | 0.00% |
| Net margin | 0.00% | (689.20%) | 0.00% |
| Free cash flow margin | 0.00% | (632.67%) | 0.00% |
| Return on equity | (173.55%) | (60.61%) | (56.36%) |
| Return on assets | (139.20%) | (41.91%) | (48.04%) |
| Return on invested capital | (3,311.00%) | 0.00% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack